MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF), a Canada-based medical biotech drug research and development company, announced on Thursday that it has established its diagnostic biomarker division with the incorporation of a wholly-owned subsidiary, MYND Diagnostics Ltd.

MYND Diagnostics Ltd's investigational range of diagnostics, novel small molecules, and biologics, is concentrated on improving disease results, monitoring and improving the treatment experience for patients suffering from Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD) and other inflammatory afflictions of the Central Nervous System. Its innovation, enabled by proprietary technology, enables quantitative and qualitative measurement of the MYND Anti-inflammatory Peptide biomarker.

Dr Lyle Oberg MD, MYND Life Sciences CEO, said, 'We are focused on supporting our drug development pipeline with the formation of MYND Diagnostics Ltd., our diagnostic biomarker division which will generate near term revenue through the commercialization of our MAP biomarker. For decades, the diagnosis of psychiatric illness relied almost exclusively on self-reporting and physician observation of symptoms to make a diagnosis. The MAP Biomarker will give healthcare providers an objective monitoring tool that will detect and diagnose mental illness earlier, thereby enabling quicker, more targeted treatments. We will deliver an accurate indicator of depression, therefore allowing for better monitoring of improving or relapsing disease.'